Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer
NCT ID: NCT01069796
Last Updated: 2016-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
64 participants
INTERVENTIONAL
2010-04-30
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer
NCT01201265
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
NCT00479674
Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer
NCT00691379
1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer
NCT01303679
Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer
NCT00868634
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Association bevacizumab paclitaxel capecitabine breast cancer
* bevacizumab 10 mg/kg in IV, D1 and D15
* paclitaxel 80mg/m2 in IV, D1 to D8 and D15
* capecitabine 1600mg/m2/D, per os, D1 to D5, Weeks 1,2 and 3
Paclitaxel
80 mg/m² weekly
Bevacizumab
10 mg/kg d1 d15
Capecitabine
800 mg/m² p.o. twice a day, D1 to D5 week 1, 2 \& 3
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Paclitaxel
80 mg/m² weekly
Bevacizumab
10 mg/kg d1 d15
Capecitabine
800 mg/m² p.o. twice a day, D1 to D5 week 1, 2 \& 3
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Measurable disease
* Patients may received prior radiotherapy as adjuvant treatment or/and metastatic disease provided that they have progressive disease at study entry
Exclusion Criteria
* HER2 positive and/or hormonal receptor positive
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ARCAGY/ GINECO GROUP
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Paul Papin
Angers, , France
Clinique Tivoli
Bordeaux, , France
Centre Hospitalier William Morey
Chalon-sur-Saône, , France
Centre Hospitalier Intercommunal
Fréjus, , France
Clinique des 4 Pavillons
Lormont, , France
Hôpital Privé Clairval
Marseille, , France
Centre Azuréen de Cancérologie
Mougins, , France
Centre Alexis Vautrin
Nancy, , France
Centre Antoine Lacassagne
Nice, , France
Centre Hospitalier Régional
Orléans, , France
Institut Jean Godinot
Reims, , France
Hôpitaux Drôme Nord - Site de Romans-sur-Isère
Romans-sur-Isère, , France
Centre Henri Becquerel
Rouen, , France
Clinique Armoricaine de Radiologie
Saint-Brieuc, , France
Clinique de l'Union
St.-Jean, , France
Centre Paul Strauss
Strasbourg, , France
Centre Hospitalier Bretagne Atlantique
Vannes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A-Taxel (GINECO BR108)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.